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ORIG INAL PAPER

Visit-to-visit blood pressure variability and sleep architecture
Xiaoyue Liu BSN, RN1 | Jeongok Logan PhD, RN1 | Younghoon Kwon MD, MS, FACC2 |
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Abstract
Visit-to-visit blood pressure (BP) variability (BPV) is an independent risk factor of car-
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diovascular disease (CVD). Sleep architecture characterizes the distribution of dif-
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ferent stages of sleep and may be important in CVD development. We examined the
association between visit-to-visit BPV and sleep architecture using in-lab polysom-
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nographic data from 3,565 patients referred to an academic sleep center. BPV was
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calculated using the intra-individual coefficient of variation of BP measures collected
12 months before the sleep study. We conducted multiple linear regression analyses to assess the association of systolic and diastolic BPV with sleep architecture—
rapid eye movement (REM) and non-rapid eye movement (NREM) sleep duration.
Our results show that systolic BPV was inversely associated with REM sleep duration (p = .058). When patients were divided into tertile groups based on their BPV,
those in the third tertile (highest variability) spent 2.7 fewer minutes in REM sleep
than those in the first tertile (lowest variability, p = .032), after adjusting for covariates. We did not find an association of systolic BPV with other measures of sleep
architecture. Diastolic BPV was not associated with sleep architecture either. In summary, our study showed that greater systolic BPV was associated with lower REM
sleep duration. Future investigation is warranted to clarify the directionality, mechanism, and therapeutic implications.
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cardiovascular system.4 Contrary to previous notions about visitto-visit BPV as a random phenomenon, it is highly reproducible in

Blood pressure (BP) is characterized by spontaneous fluctuations

clinical practice and has been known to have prognostic values for

in both the short term ranging from seconds to hours and the long

a wide range of health outcomes (eg, coronary heart disease, stroke,

1

term ranging from days to years. BP variability (BPV) results from a

and all-cause mortality).5-7 Previous work revealed that visit-to-visit

complex interplay between intrinsic cardiovascular regulation mech-

variability in systolic BP improved 8-year predictions of major CVD-

anisms, including humoral and neural central or reflex influences,

related health outcomes beyond those obtained from traditional risk

as well as extrinsic environmental and behavioral factors.2 BPV has

factors.8

been increasingly recognized as a prognostic marker of cardiovas-

Sleep also plays an essential role in cardiovascular health.

cular disease (CVD), independent of mean BP.3 In particular, visit-

Abnormal sleep duration and poor quality (eg, low sleep efficiency

to-visit BPV, which is the intra-individual BP between office visits,

and obstructive sleep apnea [OSA]) can contribute to disturbed BP

reflects the long-term fluctuations in BP and the BP burden on the

control and cardiovascular risks, such as hypertension.9,10 Sleep

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
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architecture is an objective measure of sleep quality assessed by

12 measures were randomly selected and used to compute mean

polysomnography (PSG). This parameter characterizes the distri-

BP and BPV. Considering that mean and SD of BP measures are cor-

butions of different stages, and it can be broadly classified into

related, we used the coefficient of variation (defined as SD divided

two forms: rapid eye movement (REM) and non-rapid eye move-

by the mean) as a measure of systolic BPV and diastolic BPV.4 These

11

ment including N1, N2, and N3 stages (collectively NREM).

A

limited number of studies have suggested possible implications

two indices were then grouped into tertiles of systolic BPV and diastolic BPV, respectively.

of sleep architecture in CVD.12,13 Although visit-to-visit BPV and
sleep architecture have each shown an individual link to cardiovascular health, their relationship has not been explored. In addition,

2.3 | Objective sleep measures

past research has primarily focused on short-term variations of BP
occurring over 24 hours in the context of OSA, leaving evidence

Overnight PSGs were performed using the standard channels

for long-term BPV relatively scarce.14 To address these gaps, our

recommended by the American Academy of Sleep Medicine.

study examined the association between visit-to-visit BPV and

Raw data were processed with the Embla Sandman Elite soft-

sleep architecture.

ware (Natus Medical Incorporated, California, USA) and scored
by registered PSG technologists. We employed the following

2
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2.1 | Study sample and dataset

objective sleep measures for analyses: total sleep time, sleep
architecture, and apnea–hypopnea index (AHI). For the purpose
of this study, sleep architecture was expressed as the duration
of each sleep stage (REM and NREM [N1, N2 and N3]) (minutes)
as well as their proportions relative to total sleep time (%). AHI,

We reviewed in-lab PSG from patients who were referred to the

an index determining the severity of OSA, was derived from the

Sleep Center at the University of Virginia Health System between

number of apnea and hypopnea events per hour of sleep. We

2010 and 2017. Nearly all patients were referred to the sleep center

defined apnea as a reduction in airflow greater than 90% of the

for evaluation of sleep-disordered breathing.15,16 Objective sleep

pre-event baseline and occurring for longer than 10 seconds

measures were extracted from the PSG reports. Patients’ health

using a thermocouple signal. Hypopnea events were recorded

data, including demographic characteristics, vital signs (eg, BP meas-

when the amplitude of the nasal pressure flow signal drop more

urements), medical history (diabetes and hyperlipidemia), and history

than 30% of the pre-event baseline for longer than 10 seconds.

of medication use, were extracted from their electronic medical re-

We adopted a hypopnea definition requiring at least 4% oxygen

cords and were subsequently linked to the PSG dataset. We included

desaturation (eg, Rule 1A for PSGs conducted between 2014

the patients who met the following criteria: 1) aged over 18 years,

and 2018 and Rule 4B for PSGs conducted between 2010 and

2) underwent a diagnostic PSG study, and 3) had at least three BP

2013).18,19 OSA was defined by AHI greater than 5 per hour of

measures taken during office visits within one year prior to the sleep

sleep and was further classified into four levels of severity: nor-

studies. Excluded were those who underwent split night studies,

mal (< 5.0/h), mild (5.0 - 14.9/h), moderate (15.0 - 29.9/h), and

home sleep studies, or continuous positive airway pressure titration

severe (≥ 30.0/h).

studies where sleep architecture variables were either not recorded
or limited to only a small portion of the night. This study was approved by the University of Virginia Institutional Review Board.

2.2 | Blood pressure and blood pressure variability

2.4 | Covariates
We selected the following variables from patients’ medical records
as potential confounders: demographic and biometric characteristics, mean systolic and diastolic BP, diabetes, hyperlipidemia, and

All available BP readings taken during any office visits within the

use of medications including antipsychotics, antidepressants, and

University of Virginia Health System and recorded in patients’ elec-

antihypertensives which could affect BP and/or sleep architec-

tronic medical records were extracted. We used measurements

ture. Several cardiovascular risk factors including hypertension

taken one year before the sleep studies to calculate mean and intra-

diagnosis, mean systolic BP, diabetes, hyperlipidemia, and obesity

individual standard deviation (SD). BP was measured with validated

may be potential confounders in the relationship between sys-

and regularly recalibrated Dinamap devices by registered nurses

tolic BPV and sleep architecture. They thus were identified and

following standard guidelines throughout the University of Virginia

adjusted in multivariable models. Demographic and biometric vari-

Health System.17 The number of BP readings for each patient dur-

ables included age, sex, race/ethnicity (non-Hispanic white, non-

ing the year prior to the sleep study ranged between 3 and 146,

Hispanic black, Hispanic, and other), and body mass index (BMI).

with an average of 9.8 (median = 7; interquartile range = [4, 11]). For

BMI was calculated by height and weight and was then categorized

patients who had more than 12 measures taken during this period,

into four groups (<25.0 kg/m2; 25.0-29.9 kg/m2; 30-34.9 kg/m2;

|
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≥35.0 kg/m2). Information about the prescription of antipsychotic,
antidepressant, and antihypertensive medications that are known

3

3.2 | Association of systolic BPV and diastolic BPV
with sleep architecture

to affect sleep was identified from medical records for the two
years before the sleep studies. Patients were classified as users

In unadjusted analyses, systolic BP and diastolic BP coefficients

or non-users of antipsychotic and/or antidepressant medica-

of variation were correlated with REM sleep duration at r = −.091

tions. Because calcium channel blockers have been shown to re-

(p < .001) and −0.085 (p < .001), respectively. There was an inverse

duce long-term BPV, 20 we grouped patients into three categories

association between systolic BPV and REM sleep duration (β = −22.2,

of antihypertensive medication use: non-users, calcium channel

p = .058), independent of patient demographic and biometric char-

blocker users, and users of other BP medications.

acteristics, diabetes, hyperlipidemia, mean systolic BP, medication
use, total sleep time, and AHI (Model 1, Table 3). In Model 2 where

2.5 | Statistical analysis

systolic BPV tertile was a main predictor, patients in tertile 3 (highest
variability) spent about 2.7 fewer minutes in REM sleep compared
to those in tertile 1 (lowest variability) (p = .032). This difference

All statistical analyses were performed using Stata/SE version 15

represented nearly 5% of the total REM sleep duration in this cohort.

(StataCorp, College Station, TX, USA). We computed Pearson coeffi-

On the other hand, diastolic BPV did not show any association with

cients among all pairs of predictors in the preliminary analyses to ex-

REM sleep duration. Even though patients in the higher tertiles of

amine potential collinearity among the predictors. We subsequently

diastolic BPV demonstrated shorter REM sleep duration, no signifi-

performed multicollinearity diagnostic and confirmed that our pre-

cant difference was found between tertiles 1 and 3 (Models 1 and 2,

dictors all had variance inflation factor < 4 and did not raise multicol-

Table 3). No associations were found between BPV and any NREM

linearity concerns. The patients’ health data were compared among

sleep durations.

systolic BPV tertiles using analysis of variance or chi-square tests of
independence. Multiple linear regression models were built to evaluate the cross-sectional association between visit-to-visit BPV and

4
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DISCUSSION

sleep architecture. We modeled measures of sleep architecture (N1,
N2, N3, and REM sleep time) as a function of intra-individual sys-

We found that systolic visit-to-visit BPV had an inverse association

tolic BPV and diastolic BPV, controlling for age, sex, race/ethnicity,

with REM sleep duration, independent of potential confounders in-

BMI categories, diabetes, hyperlipidemia, history of medication use,

cluding other sleep characteristics (total sleep time and OSA). When

mean systolic or diastolic BP, total sleep time, and AHI categories.

systolic BPV was divided into tertiles, patients with the highest variability (tertile 3) spent about 2.7 fewer minutes in REM sleep than

3

|

R E S U LT S

3.1 | Sample characteristics

those with the lowest variability (tertile 1). In contrast, no association was found between BPV and NREM sleep. To the best of our
knowledge, this represents the first study to investigate the association between long-term BPV and sleep architecture.
BP is a major health factor essential for cardiovascular health,

Table 1 summarizes patient demographics and biometric char-

and managing BP is one of the seven recommended health be-

acteristics stratified by systolic BPV tertiles. Our final sample

haviors included in the American Heart Association's Life's Simple

consisted of 3,565 patients (1,353 males and 2,212 females,

7. 21,22 Our findings were in accordance with prior study results

mean age of 54 ± 15 years). This was a racially and ethnically

demonstrating the importance of maintaining BP stability. 23

diverse cohort with 37% minorities. Over 91% of the sample was

Growing evidence suggests that visit-to-visit BPV has import-

either overweight or obese, 36% had diabetes, and 51% had hy-

ant prognostic values for CVD and many other adverse health

perlipidemia. The average BP of our sample was 132/76 mmHg.

outcomes. 24-26 Of note, this parameter has demonstrated a

Patients with higher systolic BPV were more likely to have ad-

comparable CVD prognosis to the 24-hour ambulatory BPV. A me-

vanced age, higher diastolic BPV, higher AHI, and be users of

ta-analysis presented hazard ratios for all-cause mortality among

antihypertensive and antipsychotic medications. Table 2 displays

three systolic BPV indices (visit-to-visit: 1.12 [1.05-1.20]; day-to-

characteristics of sleep measures and architecture. The patients

day: 1.15 [1.06-1.26]; 24-hour ambulatory: 1.11 [1.04-1.18]), with

had an average total sleep time of 339.5 ± 88.2 minutes. As ex-

visit-to-visit BPV manifesting a similar strong association with car-

pected, OSA was common (73%) in our study sample (mean AHI

diovascular and mortality outcomes in comparison with the other

was 16.5 ± 18.0/h). Higher systolic BPV was associated with

two indices. 27 Recently, several studies have proposed potential

higher AHI (p < .001). REM and NREM sleep accounted for about

mechanisms by which BPV links to cardiovascular risks, such as

17% and 84% of total sleep time, respectively. Patients with

large arterial stiffness, endothelial dysfunction, sympathetic over-

higher systolic BPV tended to have shorter REM sleep duration

activity, and autonomic imbalance. 2,28,29 Although poor sleep as

(p < .001), longer N1 sleep percentage (p = .001), and shorter N2

an established CVD risk factor is linked to altered BP responses

and N3 sleep durations.

(eg, hypertension, nocturnal non-dipping BP), how BPV might be

4
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TA B L E 1 Demographic and biometric characteristics of the sample
Systolic BPV Tertiles
All

1

2

3

Variable

N

(%)

N

(%)

N

(%)

N

(%)

All, n (Row %)

3,565

(100.0%)

1,170

(32.82%)

1,198

(33.60%)

1,197

(33.58%)

p-Value

Intra-individual Systolic BP, mean (SD)
Mean (mm Hg)

131.73

(14.72)

129.17

(13.40)

130.92

(14.75)

135.05

(15.30)

<.001

Standard
Deviation
(mm Hg)

13.89

(6.40)

7.80

(2.36)

12.99

(1.99)

20.75

(5.35)

<.001

Coefficient of
Variation

0.10

(0.04)

0.06

(0.02)

0.10

(0.01)

0.15

(0.03)

<.001

Maximum (mm
Hg)

152.26

(21.69)

139.39

(14.87)

150.07

(17.70)

167.03

(22.08)

<.001

Minimum (mm
Hg)

113.44

(14.70)

119.21

(13.29)

113.03

(14.00)

108.22

(14.66)

<.001

Number of
Measures

7.45

(3.39)

6.12

(3.04)

8.06

(3.32)

8.14

(3.42)

<.001

Intra-individual Diastolic BP, mean (SD)
Mean (mm Hg)

75.51

(8.68)

75.25

(8.56)

75.38

(8.53)

75.91

(8.94)

.142

Standard
Deviation
(mm Hg)

8.39

(3.55)

7.06

(3.13)

8.02

(3.06)

10.06

(3.73)

<.001

Coefficient of
Variation

0.11

(0.05)

0.09

(0.04)

0.11

(0.04)

0.13

(0.05)

<.001

Maximum (mm
Hg)

87.39

(11.11)

84.33

(9.95)

86.90

(10.64)

90.86

(11.67)

<.001

Minimum (mm
Hg)

64.05

(10.06)

66.31

(9.38)

63.89

(9.72)

62.00

(10.57)

<.001

Number of
Measures

7.45

(3.39)

6.12

(3.04)

8.06

(3.32)

8.14

(3.42)

<.001

Age at Time of
Sleep Study,
mean (SD)

54.17

(14.66)

51.94

(14.66)

53.90

(14.94)

56.61

(14.01)

<.001

Male Sex, N (%)

1,353

37.95%

462

39.49%

444

37.06%

447

37.34%

.414

Non-Hispanic
White

2,238

(62.78%)

759

(64.87%)

753

(62.85%)

726

(60.65%)

.019

Non-Hispanic
Black

862

(24.18%)

259

(22.14%)

290

(24.21%)

313

(26.15%)

Race/Ethnicity, N (%)

Hispanic

119

(3.34%)

40

(3.42%)

51

(4.26%)

28

(2.34%)

Other/Unknown

346

(9.71%)

112

(9.57%)

104

(8.68%)

130

(10.86%)

35.45

(8.89)

35.26

(8.63)

34.85

(8.57)

36.24

(9.37)

311

(8.72%)

96

(8.21%)

118

(9.85%)

97

(8.10%)

BMI (kg/m 2), mean
(SD)

<.001

BMI Categories
<25
25-29.9

743

(20.84%)

256

(21.88%)

247

(20.62%)

240

(20.05%)

30-34.9

848

(23.79%)

280

(23.93%)

299

(24.96%)

269

(22.47%)

.216

≥35

1,663

(46.65%)

538

(45.98%)

534

(44.57%)

591

(49.37%)

Diabetes

1,283

(35.99%)

316

(27.01%)

417

(34.81%)

550

(45.95%)

<.001

Hyperlipidemia

1,805

(50.63%)

477

(40.77%)

610

(50.92%)

718

(59.98%)

<.001

(Continues)
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TA B L E 1 (Continued)
Systolic BPV Tertiles
All
Variable

N

1
(%)

N

2
(%)

3

N

(%)

N

(%)

p-Value

<.001

Antihypertensive Use, N (%)
No Medication

1,307

(36.66%)

562

(48.03%)

444

(37.06%)

301

(25.15%)

Calcium Channel
Blocker

805

(22.58%)

177

(15.13%)

273

(22.79%)

355

(29.66%)

Other BP
Medications

1,453

(40.76%)

431

(36.84%)

481

(40.15%)

541

(45.20%)

Antipsychotic Use,
mean (SD)

366

10.27%

93

7.95%

121

10.10%

152

12.70%

<.001

Antidepressant
Use, mean (SD)

1,053

29.54%

292

24.96%

379

31.64%

382

31.91%

<.001

Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index; BP, blood pressure; BPV, blood pressure variability; REM, rapid eye movement;
SD, standard deviation.

TA B L E 2 Characteristics of sleep variables across systolic BPV tertiles
Systolic BPV Tertiles
Variable

All

1

2

3

p-Value

Total Sleep Time (min), mean (SD)

339.50 (88.20)

344.69 (84.75)

342.05 (85.49)

331.87 (93.57)

<.001

16.50 (18.00)

15.11 (16.75)

16.16 (17.14)

18.21 (19.81)

<.001

AHI, mean (SD)
AHI Categories, N (%)
<5

950 (26.65%)

344 (29.40%)

316 (6.38%)

290 (24.23%)

1,238 (34.73%)

419 (35.81%)

412 (34.39%)

407 (34.00%)

15-29.9

843 (23.65%)

256 (21.88%)

295 (24.62%)

292 (24.39%)

≥30

534 (14.98%)

151 (12.91%)

175 (14.61%)

208 (17.38%)

5-14.9

REM Percentage, mean (SD)

16.57 (9.06)

17.43 (9.08)

16.67 (9.12)

15.61 (8.88)

.009

<.001

NREM Percentage, mean (SD)
N1

9.46 (10.28)

8.75 (8.88)

9.35 (9.93)

10.27 (11.74)

.001

N2

63.12 (13.31)

62.81 (12.56)

62.89 (13.48)

63.66 (13.84)

.228

N3

12.34 (14.22)

12.90 (14.11)

12.29 (13.4)

11.85 (15.08)

.194

58.94 (37.03)

62.99 (38.42)

59.13 (36.52)

54.81 (35.72)

<.001

N1

28.41 (25.87)

27.04 (23.35)

28.71 (26.82)

29.47 (27.18)

.066

N2

214.88 (71.40)

216.69 (66.57)

215.64 (71.20)

212.35 (76.00)

.302

N3

42.90 (52.78)

45.24 (52.4)

42.93 (48.04)

40.58 (57.42)

.099

REM Duration (min), mean (SD)
NREM Duration (min), mean (SD)

Abbreviations: AHI, apnea–hypopnea index; BPV, blood pressure variability; NREM, non-rapid eye movement; REM, rapid eye movement; SD,
standard deviation.

related to sleep has not been sufficiently explored. 30 Existing stud-

sleep that constitutes about 20% of total sleep time is considered

ies were mainly focused on the association of BPV with sleep-dis-

high quality of sleep in adults.34 Lower REM percentage (16.6% of

ordered breathing, suggesting the possible contribution of OSA to

total sleep time) in our study cohort is likely attributed to high prev-

increased visit-to-visit BPV. 31,32 In this context, we hypothesized

alence of OSA, which typically results in sleep fragmentation and

that increased visit-to-visit BPV, an indicator of subclinical CVD,

reduction in REM or N3 duration as shown in this study.35 Moreover,

could be associated with poor sleep quality independent of OSA.

since REM occurs more toward late stage in sleep, shorter sleep time

REM sleep is a distinct sleep stage that encompasses several phys-

expected in an in-lab environment would be associated with reduced

iological and behavioral features, such as muscle atonia, intermittent

REM percentage and REM duration. As such, our findings may be

muscle twitches, and autonomic and respiratory activation.33 REM

more relevant in patients with OSA.

6
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TA B L E 3 Multiple linear regression of BPV (Model 1) and BPV tertiles (Model 2) on REM sleep duration
Model 1
Variable

Model 2

Estimate (95% CI)

p-Value

Estimate (95% CI)

p-Value

Systolic Blood Pressure Variability
Coefficient of Variation

-22.188

(−0.045,

0.737)

.058

Tertiles [1 (Lowest Variability)]
2

-2.251

(−0.005

0.135)

.064

3 (Highest Variability)

-2.700

(−0.005

-0.239)

.032

2

-0.468

(−0.003

1.905)

.699

3 (Highest Variability)

-1.761

(−0.004

0.658)

.154

Diastolic Blood Pressure Variability
Coefficient of Variation

-13.560

(−0.034,

7.195)

.200

Tertiles [1 (Lowest Variability)]

Note: Reference categories are in angle brackets. The models were adjusted for age, sex, race/ethnicity, BMI, diabetes, hyperlipidemia, total sleep
time, mean systolic BP, AHI, antipsychotic or antidepressant medication use, and antihypertensive medication use.
Abbreviations: BPV, blood pressure variability; CI, confidence interval.

Current investigations on REM sleep are mostly centered in

The impact of cardiovascular dysfunction on objective sleep quality

the field of behavioral science. There is wide acknowledgment of

has not been previously examined. Thus, in this study, we were moti-

the essential roles of this sleep stage in emotional regulation and

vated to examine whether BPV, a signature of autonomic dysregula-

memory consolidation.36 While the other functions of this sleep

tion of cardiovascular system,40,41 predicts poor sleep architecture.

stage remain unclear, maintaining REM sleep homeostasis is critical

The strengths of this study include using a large sample and ob-

and may be important in cardiovascular health. A few studies have

jective PSG data. Despite these strengths, several limitations should

demonstrated that REM sleep-associated OSA is independently

be noted. First, the results derived from a single-night, lab-based

related to CVD, such as hypertension, impaired glucose metabo-

PSG may not represent the patients’ natural sleep patterns because

lism, and cardiovascular end points,37,38 but the role of REM sleep

the unique assessment environment may distort their usual sleep

itself in cardiovascular health is quite limited. Pace et al39 recently

habits. Second, since the cohort consisted of patients referred for

found that REM sleep duration was significantly reduced during the

sleep studies in one single institution, generalizability of the study

first 24 hours following stroke events in animals and that increased

findings is limited. Thus, a sample collected from multiple institu-

REM latency was linked to poor functional outcomes among post-

tions is needed for more generalizable results. Third, medication use

stroke patients. Another study reported that one SD of decrease

was obtained from prescriptions on medical records and may not

in REM sleep percentage was associated with an 18% increase in

represent actual use.

risk for atrial fibrillation, after controlling for covariates including
OSA.12 Our study results were consistent with the literature, supporting the growing body of evidence that linked sleep architecture
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to cardiovascular health. Although the absolute difference in REM
sleep duration across visit-to-visit BPV tertiles was small and is of

In this study, we found that higher visit-to-visit BPV was associated

uncertain clinical significance, some clinical implications can be pos-

with sleep architecture as reflected by reduced REM sleep duration.

tulated. For example, if a patient undergoing routine PSG for OSA

The potential pathway linking long-term BPV and sleep warrants

evaluation exhibits a significant deviation of REM sleep duration

future studies to clarify the directionality, mechanisms, and thera-

(such as absence or scarcity of REM sleep), a clinician may consider

peutic implications. Such research studies may provide insights on

evaluating the patient's BP control, specifically BPV. Conversely, for

stratifying individuals at high risk of CVD and developing targeted

patients with increased BPV (eg, the SD of systolic BP greater than

clinical interventions to reduce BP fluctuations and address sleep
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10 mmHg), a clinician may consider impaired sleep quality as a pos-

problems.

sible factor.
Despite the intriguing study findings, our results require careful

AC K N OW L E D G M E N T S

interpretations. Given the cross-sectional nature of this study, it is
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